Navigation Links
Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today announced that patient dosing has commenced in its Phase 2b clinical trial of CLP-1001.  This trial, known as STEPWISE (a randomized, double-blind, multi-center STudy comparing cross-linkEd Polyelectrolyte (CLP) WIth placebo in HF SubjEcts), is designed to evaluate the safety and efficacy of CLP-1001 in addressing signs and symptoms of fluid overload in patients with congestive heart failure (HF).  CLP-1001 is a novel, non-absorbed oral polymer that acts by binding to and removing excess sodium and fluid in the GI tract independently of the kidneys.

"The objective of the STEPWISE trial is to further understand the magnitude of the effect of CLP-1001 on key measures and clinical endpoints of heart failure-induced congestion compared to current standard of care," said Howard C. Dittrich , M.D., F.A.C.C., Chief Medical Officer of Sorbent.  "Fluid overload in heart failure patients contributes importantly to hospitalizations -- including re-hospitalizations -- slows in-patient recovery, and results in poor quality of life and physical limitations.  Based on the positive clinical benefits observed in our Phase 2a clinical trial, we look forward to advancing CLP-1001 through late-stage registration studies."   

STEPWISE is a double-blind, randomized, placebo-controlled, multicenter, study designed to evaluate CLP-1001 in patients with heart failure.  Approximately 250 patients on stable, optimized, guideline heart failure therapy that have signs and symptoms of current fluid overload after a recent HF-related hospitalization will be randomized to receive 15 grams of CLP-1001 or placebo.  The primary objective of this trial is to assess the change from baseline to eight weeks across sever
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
3. Sorbent Therapeutics Appoints Jason Levin Chief Business Officer
4. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... immune therapies for operable and inoperable solid tumor cancers, announced ... the 7 th Annual Phacilitate Immunotherapy Forum in ... at Phacilitate will take place on January 26 at 10:30 ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2
... 13, 2011 Life Spine, a medical device company ... surgical treatment of spine disorders, today announced that the ... offerings and technologies at the 6th Annual Spine Technology ... 12th, 2011, in Napa, California. "Life Spine ...
... MedClean Technologies, Inc. (OTC Bulletin Board: ... the treatment and disposal of medical waste and the ... it has formed a co-marketing agreement with Covidien, a ... relationship, Covidien,s national sales force for SharpSafety products will ...
Cached Medicine Technology:MedClean Technologies Forms Co-Promotion Relationship With Covidien, Leading Global Healthcare Products Manufacturer 2MedClean Technologies Forms Co-Promotion Relationship With Covidien, Leading Global Healthcare Products Manufacturer 3
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy ... its highest annual revenues in the past three years. Today, ... wedding dresses. , According to the sales manager of the ... for them in 2015. This point can be reflected on ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
(Date:1/22/2015)... Step into a macabre world where plants hold ... Wicked Plants, the Museum’s latest featured exhibition, opens Saturday, ... and diabolical plants inside of a dilapidated, Victorian home. ... physical and neurological processes between botanicals and the human ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... -- Stretching before taking warm-up swings may hurt your ... passive, static stretching routine before taking practice swings results ... consistent ball contact," according to Jeffrey C. Gergely, of ... He compared two different warm-up routines in a group ...
... Admissions for alcohol abuse treatment have remained the same in ... the United States, while treatment rates for illegal drugs are ... a new report. The report, issued by the ... these findings: The overall rate of substance ...
... team of Johns Hopkins Children,s Center researchers has discovered ... regulates inflammation and cell death in emphysema and may ... findings, published online in the December issue of The ... new treatments to prevent lung damage caused by infections ...
... (HealthDay News) -- A disturbing new study finds that ... anesthesia to surgical patients, and those germs contribute to ... to think that the surgical drapes protect the patient ... and on our bodies. Nope! These studies provide evidence ...
... civilian personnel is counterproductive to NATO,s strategy for ... Stene after six months in the country. ... tasks, and present ourselves more clearly," she says. ... coordination in conflicts at the University of Stavanger, ...
... , Researchers at Washington University School of Medicine in St. ... contribute substantially to dangerous forms of the parasite Toxoplasma ... closer to new ways to beat Toxoplasma and ... Cell Host & Microbe , scientists show that the ROP18 ...
Cached Medicine News:Health News:Stretching Before Warm-Up Swings May Harm Golf Game 2Health News:Drug Abuse Treatment Rates on the Rise: U.S. Report 2Health News:Protein involved in cystic fibrosis also plays role in emphysema, chronic lung disease 2Health News:Protein involved in cystic fibrosis also plays role in emphysema, chronic lung disease 3Health News:Anesthesiologists Spreading Germs During Surgery: Study 2Health News:The too many faces of war -- why the war in Afghanistan is so complex 2Health News:The too many faces of war -- why the war in Afghanistan is so complex 3Health News:The too many faces of war -- why the war in Afghanistan is so complex 4Health News:Protein helps parasite survive in host cells 2
... Acid-labile subunit (ALS) is a GH dependent ... a 578 amino acid peptide with a predicted ... serum are mostly confined to a ~150 KDa ... molecule of IGF-I or IGF-II, and this unique ...
... The Medtronic SelectSecure Lead System (Model ... lead. Its unique, lumenless design allows for ... F) without sacrificing insulation thickness. The SelectSecure ... allow positioning of the lead in select ...
... glucuronide (3alpha-diol G) is the glucuronide ... of dihydrotestosterone (DHT) [1,2]. 3alpha-diol G ... 75% of the bioactivity of testosterone ... product of intracellular reduction of DHT, ...
... are polypeptide hormones which belong to ... The TGF- superfamily is a large ... control many aspects of development, reproductive ... members incude TGF-s, bone morphogenetic proteins, ...
Medicine Products: